These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 35384891)

  • 1. Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization.
    Hwang SH; Hong HS; Kim D; Kim GM; Lee HW; Lee M; Kim DY; Park MA; Yun M
    Clin Nucl Med; 2022 Jun; 47(6):e437-e443. PubMed ID: 35384891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With Very Early and Early Hepatocellular Carcinoma.
    Hwang SH; Lee JW; Cho HJ; Kim KS; Choi GH; Yun M
    Clin Nucl Med; 2017 Jan; 42(1):34-39. PubMed ID: 27775949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers.
    Takeuchi S; Rohren EM; Abdel-Wahab R; Xiao L; Morris JS; Macapinlac HA; Hassan MM; Kaseb AO
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):969-978. PubMed ID: 27942837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of volumetric and textural analysis of pretreatment 18F-fluorodeoxyglucose PET/computerized tomography images in predicting complete response to transarterial radioembolization in hepatocellular cancer.
    Karahan Şen NP; Alataş Ö; Gülcü A; Özdoğan Ö; Derebek E; Çapa Kaya G
    Nucl Med Commun; 2022 Jul; 43(7):807-814. PubMed ID: 35506284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of imaging-based parameters in patients with intermediate-stage hepatocellular carcinoma undergoing transarterial radioembolization.
    Puranik AD; Rangarajan V; Gosavi A; Shetty N; Gala K; Kulkarni S; Mohite A; Patkar S; Goel M; Shrikhande SV; Ramaswamy A; Ostwal V; Purandare NC; Agrawal A; Shah S
    Nucl Med Commun; 2021 Mar; 42(3):337-344. PubMed ID: 33306631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [
    Sachpekidis C; Enqvist O; Ulén J; Kopp-Schneider A; Pan L; Mai EK; Hajiyianni M; Merz M; Raab MS; Jauch A; Goldschmidt H; Edenbrandt L; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2293-2307. PubMed ID: 38456971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
    Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.
    Lee JW; Kang CM; Choi HJ; Lee WJ; Song SY; Lee JH; Lee JD
    J Nucl Med; 2014 Jun; 55(6):898-904. PubMed ID: 24711649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of preoperative 18F-FDG PET metabolic and volumetric parameters in predicting microvascular invasion and postoperative recurrence of hepatocellular carcinoma.
    Jiang C; Ma G; Liu Q; Song S
    Nucl Med Commun; 2022 Jan; 43(1):100-107. PubMed ID: 34456318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioembolization with
    Ho CL; Chen S; Cheung SK; Leung YL; Cheng KC; Wong KN; Wong YH; Leung TWT
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2110-2121. PubMed ID: 29948107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of 18F-FDG PET/CT indices in metastatic renal cell cancer and evaluation of revised IMDC risk model by including 18F-FDG PET-CT parameters.
    Arikan R; Ozguven S; Telli TA; Isik S; Demircan NC; Basoglu T; Yasar A; Celebi A; Filizoglu N; Ustun HS; Tinay I; Ones T; Turoglu HT; Erdil TY; Ozturk MA; Ercelep O; Bayoglu V; Kostek O; Dane F; Yumuk PF
    Acta Radiol; 2023 May; 64(5):2040-2049. PubMed ID: 36447438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of Early Posttreatment PET/CT Evaluation Using FDG or
    Reizine E; Chalaye J; Mule S; Regnault H; Perrin C; Calderaro J; Laurent A; Amaddeo G; Kobeiter H; Tacher V; Itti E; Luciani A
    AJR Am J Roentgenol; 2022 Feb; 218(2):359-369. PubMed ID: 34494448
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic significance of metabolic tumor volume and total lesion glycolysis in patients with advanced cervical carcinoma.
    Calles-Sastre L; Mucientes-Rasilla J; San-Frutos Llorente LM; Royuela A; Garcia-Espantaleón Navas M; Herrero Gámiz S; Pérez-Medina T
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):17-21. PubMed ID: 30366731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
    Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
    Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0.
    Shady W; Kishore S; Gavane S; Do RK; Osborne JR; Ulaner GA; Gonen M; Ziv E; Boas FE; Sofocleous CT
    Eur J Radiol; 2016 Jun; 85(6):1224-31. PubMed ID: 27161074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
    Wu LL; Liang JH; Wang L; Xu W; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.